Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Long-Term Investments (2017 - 2025)

Historic Long-Term Investments for Anaptysbio (ANAB) over the last 9 years, with Q3 2025 value amounting to $7.7 million.

  • Anaptysbio's Long-Term Investments fell 7242.24% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year decrease of 7242.24%. This contributed to the annual value of $35.5 million for FY2024, which is 3124.4% up from last year.
  • Latest data reveals that Anaptysbio reported Long-Term Investments of $7.7 million as of Q3 2025, which was down 7242.24% from $28.0 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Long-Term Investments registered a high of $147.5 million during Q3 2022, and its lowest value of $5.5 million during Q2 2021.
  • For the 5-year period, Anaptysbio's Long-Term Investments averaged around $54.1 million, with its median value being $40.2 million (2023).
  • In the last 5 years, Anaptysbio's Long-Term Investments plummeted by 8594.84% in 2021 and then skyrocketed by 227025.89% in 2022.
  • Quarter analysis of 5 years shows Anaptysbio's Long-Term Investments stood at $67.1 million in 2021, then skyrocketed by 113.03% to $142.9 million in 2022, then tumbled by 81.09% to $27.0 million in 2023, then surged by 31.24% to $35.5 million in 2024, then plummeted by 78.3% to $7.7 million in 2025.
  • Its Long-Term Investments was $7.7 million in Q3 2025, compared to $28.0 million in Q2 2025 and $43.0 million in Q1 2025.